Pharma intelligence in minutes,
not meetings.
FDA approvals, trials, patents, pipelines — into clear decisions, fast.
Try:
·
·
·
·
·
8,600+ drugs · 152,000+ trials · 1,300+ patent landscapes · Updated weekly.
Start 30-day Pro trial — free →
No credit card required
Questions TheraRadar answers
Tap any question to jump straight to the data.
Recent FDA Approvals
Updated Sep 20, 2026
Upcoming FDA Decisions
Full calendarWinrevair (sotatercept)
Merck & Co., Inc.
September 21, 2026
1d away
Zilganersen
Ionis Pharmaceuticals, Inc.
September 22, 2026
2d away
Zilurgisertib
Mirum Pharmaceuticals, Inc.
September 26, 2026
6d away
From the briefs
Plain-English deep dives on the science and strategy behind the drugs.
How to Read a Cancer Trial and Tell If Patients Live Longer A cancer drug 'works.' But did patients live longer, or did a tumor just shrink? The answer is which endpoint the trial made its primary measure. Here is how to read it. 8 min read The Daraxonrasib Success Story How RAS went from "undruggable" to Rasonque, the first RAS-targeted medicine to extend survival in pancreatic cancer, and the best reporting and science behind it. 6 min read Can an IBD Biologic Last Six Months? Several companies want to stretch IBD antibodies from a shot every few weeks to one every three months, or even six. Keeping the drug in the blood that long is the easy part. Whether the disease stays controlled right up to the next dose is the hard part, and the bet the newest programs are making. 8 min read Does Blocking IL-17F Actually Matter? Two of the newest PsA drugs block IL-17F as well as IL-17A; the older ones block only IL-17A. A plain walk through what the extra target actually buys: clear help on the skin, no proven help on the joints yet, and a fungal cost in the middle. 10 min read Fifteen Drugs by Blocking. None by Switching On. The TNF receptor superfamily has produced fifteen approved medicines, and every one of them works by shutting something down. Six receptors have been pushed the other way for twenty years, and not one agonist antibody has been approved. 14 min read The Disease That Wasn't Rare After All The scan that finds it is quick, safe, and has been around for years. Almost no cardiologist used it until a drug gave them a reason to look. 11 min read
Pro tools
Pre-built analyses. The slow research is already done.
🧬
Competitive heatmaps
90+ interactive grids — indication landscapes (company × mechanism), company portfolios, and MOA platforms. Click any cell to drill into the trials.
⚖️
Compare two companies
Head-to-head comparison of any two company portfolios — pipeline, approvals, and revenue side by side.
🔬
Clinical Trials Explorer
Search and filter 152,000+ trials by drug, sponsor, phase, and condition.
📉
Patent Cliff with revenue arcs
Humira -73%, Revlimid -81%, Stelara -43% — actual SEC revenue declines, not Medicare proxies.
Data sources: FDA Drugs@FDA, ClinicalTrials.gov, Orange Book, SEC EDGAR.
Data updated: Sep 20, 2026